{"id":"oral-antipsychotic-medication","safety":{"commonSideEffects":[{"rate":"null","effect":"Weight gain"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Oral antipsychotic medications like this one work by blocking dopamine receptors in the brain, which helps to reduce symptoms of psychosis such as hallucinations and delusions. This can help improve mood and cognitive function in individuals with schizophrenia and other mental health conditions.","oneSentence":"Blocks dopamine receptors in the brain to help manage psychosis symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:45.123Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of schizophrenia"},{"name":"Treatment of bipolar disorder"}]},"trialDetails":[{"nctId":"NCT06474195","phase":"NA","title":"Cue-based Intervention in Prospective Memory and Medication Adherence.","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pittsburgh","startDate":"2024-06-15","conditions":"Schizophrenia","enrollment":104},{"nctId":"NCT05999240","phase":"PHASE2","title":"Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder","status":"RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2025-10-01","conditions":"Autism Spectrum Disorder","enrollment":30},{"nctId":"NCT05110157","phase":"PHASE3","title":"Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2021-11-29","conditions":"Schizophrenia","enrollment":442},{"nctId":"NCT04860830","phase":"PHASE3","title":"CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-08-09","conditions":"Schizophrenia","enrollment":609},{"nctId":"NCT06997198","phase":"PHASE4","title":"Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities","status":"NOT_YET_RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2026-03-01","conditions":"Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities","enrollment":25},{"nctId":"NCT07356765","phase":"NA","title":"Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms","status":"ENROLLING_BY_INVITATION","sponsor":"Tianjin Anding Hospital","startDate":"2023-09-26","conditions":"Schizophrenia, Negative Symptoms of Schizophrenia","enrollment":120},{"nctId":"NCT07363577","phase":"PHASE3","title":"Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"LB Pharmaceuticals Inc.","startDate":"2026-03","conditions":"Schizophrenia","enrollment":456},{"nctId":"NCT06869187","phase":"PHASE2","title":"Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults","status":"RECRUITING","sponsor":"Autobahn Therapeutics, Inc.","startDate":"2025-03-28","conditions":"Bipolar Disorder Depression","enrollment":35},{"nctId":"NCT06961968","phase":"PHASE3","title":"Randomized Withdrawal Study in Patients With Schizophrenia","status":"RECRUITING","sponsor":"Vanda Pharmaceuticals","startDate":"2025-05-14","conditions":"Schizophrenia","enrollment":400},{"nctId":"NCT01626885","phase":"PHASE2, PHASE3","title":"A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":42},{"nctId":"NCT01626859","phase":"PHASE2, PHASE3","title":"A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":38},{"nctId":"NCT01625897","phase":"PHASE2, PHASE3","title":"A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":125},{"nctId":"NCT01625000","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of MP-214 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":512},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT05628103","phase":"PHASE3","title":"A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-12-19","conditions":"Schizophrenia","enrollment":101},{"nctId":"NCT06474286","phase":"NA","title":"Prucalopride for Cognitive Functioning in Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"University of Pittsburgh","startDate":"2026-07-31","conditions":"Schizophrenia","enrollment":34},{"nctId":"NCT01543321","phase":"PHASE3","title":"Xenazine in Late Dyskinetic Syndrome With Neuroleptics","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2012-05-14","conditions":"Tardive Dyskinesia","enrollment":54},{"nctId":"NCT06179108","phase":"PHASE2","title":"Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"LB Pharmaceuticals Inc.","startDate":"2023-11-29","conditions":"Schizophrenia","enrollment":359},{"nctId":"NCT07206563","phase":"PHASE1, PHASE2","title":"Penfluridol for Relapsed/Refractory Small Cell Cancers","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-10-01","conditions":"Small Cell Carcinoma, Small Cell Carcinoma of Lung, Small Cell Lung Cancer ( SCLC )","enrollment":33},{"nctId":"NCT02282761","phase":"PHASE3","title":"A Trial to Assess the Antipsychotic Efficacy of ITI-007","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2014-11","conditions":"Schizophrenia","enrollment":450},{"nctId":"NCT02469155","phase":"PHASE3","title":"A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2015-06","conditions":"Schizophrenia","enrollment":696},{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT03121586","phase":"PHASE3","title":"Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia","status":"TERMINATED","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2017-01","conditions":"Schizophrenia","enrollment":995},{"nctId":"NCT04531982","phase":"PHASE3","title":"Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia","status":"COMPLETED","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2020-08-05","conditions":"Schizophrenia","enrollment":454},{"nctId":"NCT02634463","phase":"PHASE1","title":"Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-11-09","conditions":"Immunoassay, Antipsychotic","enrollment":81},{"nctId":"NCT05744479","phase":"PHASE4","title":"Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-02-28","conditions":"Intellectual Disability, Developmental Disability, Obesity","enrollment":100},{"nctId":"NCT01825798","phase":"PHASE3","title":"Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)","status":"COMPLETED","sponsor":"Holland Bloorview Kids Rehabilitation Hospital","startDate":"2013-04","conditions":"Overweight, Autism Spectrum Disorder","enrollment":60},{"nctId":"NCT06756139","phase":"NA","title":"Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia","status":"RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2024-11-01","conditions":"Functional Dyspepsia, Self-help Mobile Cognitive Behavioral Therapy, Antipsychotic Drug","enrollment":88},{"nctId":"NCT07011693","phase":"PHASE4","title":"Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I)","status":"NOT_YET_RECRUITING","sponsor":"Xinyu Zhou","startDate":"2025-06-20","conditions":"Major Depressive Disorder (MDD)","enrollment":400},{"nctId":"NCT03351244","phase":"PHASE2","title":"This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2017-12-07","conditions":"Schizophrenia","enrollment":264},{"nctId":"NCT03666715","phase":"","title":"A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"2018-08-07","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT03629951","phase":"","title":"A Study for Schizophrenia Relapse Prediction","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-29","conditions":"Schizophrenia","enrollment":333},{"nctId":"NCT00460512","phase":"PHASE3","title":"An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2007-04-25","conditions":"Schizophrenia","enrollment":1814},{"nctId":"NCT06878833","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder","status":"WITHDRAWN","sponsor":"Lyndra Inc.","startDate":"2025-04-18","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":""},{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762},{"nctId":"NCT06787781","phase":"NA","title":"Metabolic and Clinical Effect of Alpha-lipoic Acid Administration in Schizophrenic Subjects","status":"COMPLETED","sponsor":"University of Messina","startDate":"2021-06-01","conditions":"Metabolic Evaluation, Cardiac Complications","enrollment":15},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT06838104","phase":"NA","title":"Effect of Melatonin on Schizophrenic Symptoms: a Randomized Placebo-Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lahore General Hospital","startDate":"2024-12-05","conditions":"Schizophrenia Disorders, Psychotic Disorder","enrollment":76},{"nctId":"NCT02515773","phase":"PHASE4","title":"Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs","status":"COMPLETED","sponsor":"Melissa Delbello","startDate":"2015-12","conditions":"Bipolar Disorder","enrollment":1565},{"nctId":"NCT00254202","phase":"PHASE3","title":"Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia","status":"COMPLETED","sponsor":"Vanda Pharmaceuticals","startDate":"2005-11-18","conditions":"Schizophrenia","enrollment":593},{"nctId":"NCT03994965","phase":"PHASE2","title":"The Sub-Sero Study","status":"WITHDRAWN","sponsor":"Bjorn H. Ebdrup","startDate":"2024-12-01","conditions":"Schizophrenia, Psychosis","enrollment":""},{"nctId":"NCT05654870","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia","status":"TERMINATED","sponsor":"Neurocrine Biosciences","startDate":"2023-01-05","conditions":"Schizophrenia","enrollment":8},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT05326347","phase":"PHASE3","title":"A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2022-05-31","conditions":"Schizophrenia","enrollment":190},{"nctId":"NCT06107829","phase":"PHASE4","title":"Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities","status":"WITHDRAWN","sponsor":"Stephen Ruedrich","startDate":"2025-01","conditions":"Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities","enrollment":""},{"nctId":"NCT01029769","phase":"NA","title":"Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2009-12","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":350},{"nctId":"NCT03818256","phase":"PHASE2","title":"A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2019-12-04","conditions":"Antipsychotic-induced Weight Gain (AIWG)","enrollment":71},{"nctId":"NCT06251635","phase":"NA","title":"Effects of Antipsychotics on Brain Insulin Action in Females","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2024-06-03","conditions":"Insulin Resistance, Menstrual Cycle, Type 2 Diabetes","enrollment":15},{"nctId":"NCT05402111","phase":"PHASE1","title":"A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-06-13","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT05542264","phase":"PHASE1","title":"A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-15","conditions":"Schizophrenia","enrollment":19},{"nctId":"NCT04524403","phase":"PHASE2","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2020-09-09","conditions":"Antipsychotic-induced Weight Gain (AIWG)","enrollment":150},{"nctId":"NCT01908192","phase":"PHASE2, PHASE3","title":"Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®","status":"TERMINATED","sponsor":"SyneuRx International (Taiwan) Corp","startDate":"2014-06","conditions":"Schizophrenia","enrollment":60},{"nctId":"NCT06331520","phase":"PHASE3","title":"NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-05-01","conditions":"Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy","enrollment":627},{"nctId":"NCT06301074","phase":"PHASE1","title":"The Phase I Study of HS-10509 in Chinese Adult Subjects","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2024-03","conditions":"Schizophrenia","enrollment":80},{"nctId":"NCT03101319","phase":"NA","title":"Role of Vitamin D Supplementation in Schizophrenia","status":"COMPLETED","sponsor":"Central Institute of Psychiatry, Ranchi, India","startDate":"2019-04-08","conditions":"Schizophrenia","enrollment":73},{"nctId":"NCT06238089","phase":"","title":"Anti-psychotic Drug Prescribing Patterns Within Specialist Adult ID Services in England and Wales","status":"UNKNOWN","sponsor":"University of Plymouth","startDate":"2023-12-19","conditions":"Intellectual Disability","enrollment":600},{"nctId":"NCT05554627","phase":"PHASE4","title":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","status":"WITHDRAWN","sponsor":"VA Office of Research and Development","startDate":"2023-10-27","conditions":"Depressive Disorder, Major","enrollment":""},{"nctId":"NCT04203056","phase":"PHASE4","title":"Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2019-12-16","conditions":"Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder","enrollment":15},{"nctId":"NCT01481883","phase":"PHASE4","title":"Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?","status":"COMPLETED","sponsor":"The Alfred","startDate":"2012-01","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":13},{"nctId":"NCT05857566","phase":"PHASE1","title":"Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine","status":"COMPLETED","sponsor":"Response Pharmaceuticals","startDate":"2023-05-16","conditions":"Drug-induced Weight Gain","enrollment":24},{"nctId":"NCT05762146","phase":"PHASE2","title":"Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE","status":"UNKNOWN","sponsor":"Maastricht University","startDate":"2022-09-05","conditions":"Ischemic Stroke, Acute","enrollment":28},{"nctId":"NCT06060886","phase":"PHASE4","title":"Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis","status":"UNKNOWN","sponsor":"Consorcio Centro de Investigación Biomédica en Red (CIBER)","startDate":"2023-11-01","conditions":"Schizophrenia, Treatment-resistant Schizophrenia, Side Effect","enrollment":244},{"nctId":"NCT05964790","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With Schizophrenia","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2023-07-30","conditions":"Schizophrenia","enrollment":112},{"nctId":"NCT01291511","phase":"PHASE3","title":"Relapse Prevention Study in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Vanda Pharmaceuticals","startDate":"2011-02","conditions":"Schizophrenia","enrollment":635},{"nctId":"NCT04421456","phase":"PHASE2","title":"Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2020-08-18","conditions":"Schizophrenia","enrollment":95},{"nctId":"NCT05830708","phase":"NA","title":"The Efficacy of Probiotics for the Treatment of Alcohol Use Disorder Among Adult Males","status":"NOT_YET_RECRUITING","sponsor":"Universiti Sains Malaysia","startDate":"2023-05-01","conditions":"Alcohol Use Disorder","enrollment":120},{"nctId":"NCT00330551","phase":"PHASE4","title":"Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2006-03","conditions":"Schizophrenia","enrollment":126},{"nctId":"NCT00845026","phase":"PHASE2","title":"A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2009-03","conditions":"Schizophrenia","enrollment":261},{"nctId":"NCT03788759","phase":"PHASE2, PHASE3","title":"Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia","status":"COMPLETED","sponsor":"Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara","startDate":"2019-09-01","conditions":"Schizophrenia, Oxidative Stress","enrollment":48},{"nctId":"NCT04291469","phase":"NA","title":"Antipsychotic Effects of Probiotics and Prebiotics on Patients With Schizophrenia","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-03-03","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT02184767","phase":"PHASE1","title":"Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"BiPolar","enrollment":30},{"nctId":"NCT04327843","phase":"PHASE3","title":"Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)","status":"COMPLETED","sponsor":"Case Western Reserve University","startDate":"2019-11-05","conditions":"Schizophrenia, Medication Nonadherence, Schizo Affective Disorder","enrollment":22},{"nctId":"NCT02286206","phase":"PHASE4","title":"Study of the Effect of Dosing on Clozapine Levels","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2015-01","conditions":"Psychotic Disorders, Schizophrenia","enrollment":""},{"nctId":"NCT02213887","phase":"PHASE4","title":"Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2014-09","conditions":"Psychotic Disorders, Gastroesophageal Reflux","enrollment":""},{"nctId":"NCT01866098","phase":"NA","title":"Naltrexone for Antipsychotic-Induced Weight Gain","status":"COMPLETED","sponsor":"Yale University","startDate":"2013-05","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":144},{"nctId":"NCT01738698","phase":"PHASE3","title":"Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia","status":"TERMINATED","sponsor":"Shire","startDate":"2012-11-01","conditions":"Schizophrenia","enrollment":4},{"nctId":"NCT01760993","phase":"PHASE3","title":"Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia","status":"TERMINATED","sponsor":"Shire","startDate":"2013-02-01","conditions":"Schizophrenia","enrollment":2},{"nctId":"NCT00922272","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms","status":"COMPLETED","sponsor":"Shire","startDate":"2009-09-14","conditions":"Schizophrenia and Predominant Negative Symptoms","enrollment":92},{"nctId":"NCT04461119","phase":"PHASE2","title":"Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2020-06-16","conditions":"Schizophrenia","enrollment":138},{"nctId":"NCT03565068","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-20","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT03319953","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2017-12-21","conditions":"Stable Schizophrenia","enrollment":23},{"nctId":"NCT00159757","phase":"PHASE4","title":"12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-11","conditions":"Schizophrenia","enrollment":150},{"nctId":"NCT02970305","phase":"PHASE2","title":"Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)","status":"COMPLETED","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2016-11-04","conditions":"Schizophrenia","enrollment":403},{"nctId":"NCT02442817","phase":"PHASE4","title":"Linagliptin and Mesenchymal Stem Cells: A Pilot Study","status":"COMPLETED","sponsor":"University of Nevada, Reno","startDate":"2015-03-02","conditions":"Schizophrenia","enrollment":10},{"nctId":"NCT03863691","phase":"NA","title":"Influence of Dopaminergic Blockade on Stress Responses, Motivation and Emotional Reactivity in Humans.","status":"COMPLETED","sponsor":"Philipps University Marburg","startDate":"2019-04-15","conditions":"Healthy Participants","enrollment":85},{"nctId":"NCT02146547","phase":"PHASE4","title":"European Long-acting Antipsychotics in Schizophrenia Trial","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2015-02","conditions":"Schizophrenia","enrollment":536},{"nctId":"NCT00712270","phase":"PHASE4","title":"Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia","status":"TERMINATED","sponsor":"Kettering Health Network","startDate":"2005-04","conditions":"Schizophrenia","enrollment":21},{"nctId":"NCT03568500","phase":"PHASE4","title":"A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-05-21","conditions":"Schizophrenia, Schizoaffective Disorder, First Episode Psychosis","enrollment":44},{"nctId":"NCT02970292","phase":"PHASE3","title":"Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)","status":"COMPLETED","sponsor":"ACADIA Pharmaceuticals Inc.","startDate":"2016-10-26","conditions":"Schizophrenia","enrollment":396},{"nctId":"NCT00458211","phase":"PHASE4","title":"Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics","status":"COMPLETED","sponsor":"Bronx Psychiatric Center","startDate":"2005-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":40},{"nctId":"NCT01913327","phase":"PHASE4","title":"Antipsychotic Effects on Brain Function in Schizophrenia","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2013-04","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":4},{"nctId":"NCT02717130","phase":"NA","title":"Aripiprazole, Abilify Maintena Collaborative Clinical Protocol","status":"TERMINATED","sponsor":"Florida Atlantic University","startDate":"2016-06-08","conditions":"Schizophrenia","enrollment":9},{"nctId":"NCT03284294","phase":"PHASE3","title":"Influence of Vitamin D Supplementation on Serum BDNF Level and Cognitive Function in Schizophrenia","status":"UNKNOWN","sponsor":"Universitas Padjadjaran","startDate":"2020-04-15","conditions":"Schizophrenia","enrollment":40},{"nctId":"NCT02181803","phase":"PHASE1","title":"MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-05","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT00333177","phase":"PHASE4","title":"Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2006-03","conditions":"Schizophrenia","enrollment":92},{"nctId":"NCT02532491","phase":"PHASE4","title":"Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up","status":"UNKNOWN","sponsor":"Fundación Marques de Valdecilla","startDate":"2014-05","conditions":"Schizophrenia, Psychotic Disorders","enrollment":200},{"nctId":"NCT03883204","phase":"PHASE4","title":"Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up","status":"UNKNOWN","sponsor":"Fundación Marques de Valdecilla","startDate":"2015-01-01","conditions":"Schizophrenia, Psychotic Disorders, Psychosis","enrollment":115},{"nctId":"NCT03790345","phase":"PHASE2, PHASE3","title":"Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics","status":"UNKNOWN","sponsor":"Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara","startDate":"2019-09-03","conditions":"Schizophrenia, Drug Induced Movement Disorder, Unspecified, Oxidative Stress","enrollment":45},{"nctId":"NCT03643159","phase":"PHASE4","title":"A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-06-28","conditions":"Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder","enrollment":2},{"nctId":"NCT01104792","phase":"PHASE3","title":"Long-term Study of Cariprazine in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2010-05-31","conditions":"Schizophrenia","enrollment":752}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":49,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"oral antipsychotic medication","genericName":"oral antipsychotic medication","companyName":"US Department of Veterans Affairs","companyId":"us-department-of-veterans-affairs","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Blocks dopamine receptors in the brain to help manage psychosis symptoms. Used for Treatment of schizophrenia, Treatment of bipolar disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}